QUESTION: Which disorder has been approved for treatment with Alk inhibitors?

IDEAL_ANSWER:
- Anaplastic lymphoma kinase (ALK) rearrangement is detected in 3-7% of patients with non-small-cell lung cancer. Crizotinib is an ALK inhibitor, which was approved in 2011 for the treatment of ALK-positive lung cancer.
- Crizotinib was approved to treat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) by the Food and Drug Administration in 2011

EXACT_ANSWER:
- ALK-positive lung cancer